{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T23:07:31Z","timestamp":1772579251299,"version":"3.50.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,1,5]],"date-time":"2015-01-05T00:00:00Z","timestamp":1420416000000},"content-version":"vor","delay-in-days":491,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Bone Oncology"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.jbo.2013.05.001","type":"journal-article","created":{"date-parts":[[2013,5,15]],"date-time":"2013-05-15T17:25:19Z","timestamp":1368638719000},"page":"123-131","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["A systematic review of dosing frequency with bone-targeted agents for patients with bone metastases from breast cancer"],"prefix":"10.1016","volume":"2","author":[{"given":"Brian","family":"Hutton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina L.","family":"Addison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaitryn","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dean","family":"Fergusson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sasha","family":"Mazarello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Clemons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jbo.2013.05.001_bib1","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/bjc.1998.52","article-title":"Clinical course and prognostic factors following bone recurrence from breast cancer","volume":"77","author":"Coleman","year":"1998","journal-title":"British Journal of Cancer"},{"issue":"12","key":"10.1016\/j.jbo.2013.05.001_bib2","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1007\/s00520-004-0671-9","article-title":"Bisphosphonate use for the management of breast cancer patients with bone metastases: a survey of Canadian Medical Oncologists","volume":"12","author":"Verma","year":"2004","journal-title":"Supportive Care in Cancer"},{"key":"10.1016\/j.jbo.2013.05.001_bib3","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1177\/154405910708601102","article-title":"Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates","volume":"86","author":"Kimmel","year":"2007","journal-title":"Journal of Dental Research"},{"issue":"9","key":"10.1016\/j.jbo.2013.05.001_bib4","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1158\/1078-0432.CCR-11-2944","article-title":"Denosumab dose selection for patients with bone metastases from solid tumor","volume":"18","author":"Doshi","year":"2012","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.jbo.2013.05.001_bib5","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.jbo.2013.05.001_bib6","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1007\/s00520-011-1230-9","article-title":"Optimising the use of bone-targeted agents in patients with metastatic cancers: a practical guide for medical oncologists","volume":"19","author":"Bouganim","year":"2001","journal-title":"Supportive Care in Cancer"},{"issue":"5","key":"10.1016\/j.jbo.2013.05.001_bib7","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3747\/co.19.1011","article-title":"Bone-targeted agents and skeletal- related events in breast cancer patients with bone metastases: the state of the art","volume":"19","author":"Clemons","year":"2012","journal-title":"Current Oncology"},{"issue":"5","key":"10.1016\/j.jbo.2013.05.001_bib8","doi-asserted-by":"crossref","first-page":"e303","DOI":"10.3747\/co.19.1009","article-title":"Time to put an end to the \u201cone size fits all\u201d approach to bisphosphonate use in patients with metastatic breast cancer?","volume":"19","author":"Kuchuk","year":"2012","journal-title":"Current Oncology"},{"issue":"1","key":"10.1016\/j.jbo.2013.05.001_bib9","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jbo.2012.12.001","article-title":"Oral care and use of bone-targeted agents in patients with metastatic cancers: a practical guide for dental surgeons and oncologists","volume":"2","author":"Kuchuk","year":"2013","journal-title":"Journal of Bone Oncology"},{"issue":"9005","key":"10.1016\/j.jbo.2013.05.001_bib10","article-title":"ZOOM: a prospective, randomized trial of zoledronic acid (ZOL; q 4wk vs q 12wk) for long-term treatment in patients with bone metastatic breast cancer (BC) after 1yr of standard ZOL treatment","volume":"30","author":"Amadori","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.jbo.2013.05.001_bib11","article-title":"Randomized feasibility study of de-escalated (every 12wk) versus standard (every 3 to 4wk) intravenous pamidronate in women with low-risk bone metastases from breast cancer","author":"Amir","year":"2012","journal-title":"American Journal of Clinical Oncology"},{"issue":"2","key":"10.1016\/j.jbo.2013.05.001_bib12","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/nrclinonc.2011.198","article-title":"Bone cancer in 2011: prevention and treatment of bone metastases","volume":"9","author":"Coleman","year":"2011","journal-title":"Nature Reviews Clinical Oncology"},{"key":"10.1016\/j.jbo.2013.05.001_bib13","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/jco.2012.30.15_suppl.511","article-title":"Randomized trial of marker-directed versus standard schedule zoledronic acid for bone metastases from breast cancer","author":"Coleman","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.jbo.2013.05.001_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2012.09.001","article-title":"A national portfolio of bone oncology trials\u2014the Canadian experience in 2012","author":"Kuchuk","year":"2012","journal-title":"Journal of Bone Oncology"},{"issue":"10","key":"10.1016\/j.jbo.2013.05.001_bib15","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"62","author":"Liberati","year":"2009","journal-title":"Journal of Clinical Epidemiology"},{"issue":"1","key":"10.1016\/j.jbo.2013.05.001_bib16","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Controlled Clinical Trials"},{"key":"10.1016\/j.jbo.2013.05.001_bib17","unstructured":"Higgins JPT, Green S. (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration; 2011 [updated March 2011]."},{"issue":"28","key":"10.1016\/j.jbo.2013.05.001_bib18","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1200\/JCO.2007.11.8604","article-title":"Randomized active controlled phase II study of denosumab efficacy and safety in patients with breast cancer related bone metastases","volume":"25","author":"Lipton","year":"2007","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.jbo.2013.05.001_bib19","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO;2-0","article-title":"Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases: a double blind, randomized dose-response study","volume":"91","author":"Berenson","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.jbo.2013.05.001_bib20","doi-asserted-by":"crossref","first-page":"9111","DOI":"10.1200\/jco.2012.30.15_suppl.9111","article-title":"Continued suppression of bone turnover following a single dose of zoledronic acid: time to re-think dosing intervals in the management of bone metastases?","author":"Simmons","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"24 Suppl","key":"10.1016\/j.jbo.2013.05.001_bib21","article-title":"Evaluating efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal related events. TRIUMPH: a pragmatic multicentre trial","volume":"72","author":"Bouganim","year":"2012","journal-title":"Cancer Research"},{"key":"10.1016\/j.jbo.2013.05.001_bib22","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1200\/JCO.2002.06.037","article-title":"American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma","volume":"20","author":"Berenson","year":"2002","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.jbo.2013.05.001_bib23","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s10549-007-9583-y","article-title":"Phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy","volume":"108","author":"Clemons","year":"2008","journal-title":"Breast Cancer Research and Treatment"},{"key":"10.1016\/j.jbo.2013.05.001_bib24","doi-asserted-by":"crossref","first-page":"4895","DOI":"10.1200\/JCO.2006.05.9212","article-title":"Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy","volume":"24","author":"Clemons","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.jbo.2013.05.001_bib25","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.2174\/138161210791034003","article-title":"Bisphosphonates as treatment of bone metastases","volume":"16","author":"Holen","year":"2010","journal-title":"Current Pharmaceutical Design"}],"container-title":["Journal of Bone Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137413000249?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137413000249?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:15:25Z","timestamp":1761941725000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212137413000249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S2212137413000249"],"URL":"https:\/\/doi.org\/10.1016\/j.jbo.2013.05.001","relation":{},"ISSN":["2212-1374"],"issn-type":[{"value":"2212-1374","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A systematic review of dosing frequency with bone-targeted agents for patients with bone metastases from breast cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Bone Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbo.2013.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier GmbH.","name":"copyright","label":"Copyright"}]}}